News

The InfectoGnostics Research Campus Jena presented itself at this year's MEDICA trade fair in Düsseldorf from November 12 to 15, 2018. The "RamanBioAssay" for photonic detection of antibiotic resistance was presented at the joint Middle German stand "Forschung für die Zukunft / Research for the…

The Geneva Foundation for Innovative New Diagnostics (FIND) will fund feasibility studies on molecular point-of-care tests for hepatitis C by the two InfectoGnostics industrial partners Abbott (Alere Technologies) and BLINK. This was announced by FIND on 28 July, World Hepatitis Day.

The Jena scientists Prof. Ute Neugebauer and Prof. Juergen Popp were awarded the 3rd prize of the Berthold Leibinger Innovationspreis 2018 for their light-based method for the rapid determination of antibiotic resistance.

The “CarbDetect AS-2” molecular resistance test is the first product developed through collaboration at the InfectoGnostics research campus. A clinical study in Pakistan now shows that this cost-effective test meets the requirements for use in clinical laboratories: With a reliability of 98.8%, the…

The InfectoGnostics Research Campus Jena is an important driver of the Smart Specialization Platform (S3) "European Photonics Alliance". As a result, the network has become a member of the European Cluster Collaboration Platform (ECCP) in March, increasing its visibility in Europe. The two platforms…

Multi-resistant germs are a growing health threat. The frequent and often unnecessary use of antibiotics means that more and more pathogens are insensitive to drugs. Infections that can be treated well so far, can be life-threatening in the future. A novel rapid test provides information within 3…

The two BMBF-funded research campuses InfectoGnostics and M²OLIE (Mannheim Molecular Intervention Environment) met in early February for a joint workshop in Jena. The focus was on research approaches of the campi, which could complement each other. Discussions included the combination of different…